Trials / Completed
CompletedNCT05742594
A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants
A Phase 1, Open-label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the bioequivalence of four different lazertinib oral tablet formulations in healthy adult participants under fasted condition.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lazertinib | Lazertinib will be administered orally. |
Timeline
- Start date
- 2023-01-03
- Primary completion
- 2023-03-31
- Completion
- 2023-04-03
- First posted
- 2023-02-24
- Last updated
- 2023-06-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05742594. Inclusion in this directory is not an endorsement.